News Articles

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age... INGELHEIM, Germany & INDIANAPOLIS, US -Monday 13 June 2016  

In a separate analysis, Jardiance® also reduced risk for CV events consistently in groups divided by LDL cholesterol level Results from sub-analyses of the landmark EMPA-REG OUTCOME® trial presented at the American Diabetes Association 76th Scientific Sessions® (BUSINESS...

LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the... -Monday 9 May 2016

The trial will evaluate efficacy and safety of nintedanib* as a first-line oral treatment in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy Nintedanib targets receptors that play a role in tumour growth and development of metastasis in malignant...

The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled... -Friday 8 April 2016  

• New post-hoc analysis shows routine eosinophil blood test could help identify the small group of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study1 benefited from addition of ICS on top of Spiriva®‡ and a...

New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype1,2,3 -Tuesday 8 March 2016  

SPIRIVA® Respimat® shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies4 New analyses show improved lung function5 and asthma symptom control and reduced asthma exacerbations for patients...

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds -Monday 7 March 2016

AbbVie and Boehringer Ingelheim will share responsibility for future clinical development and establish a Joint Steering Committee Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy over ustekinumab in Phase 2 clinical studies with a potential for quarterly...

New survey gives voice to people living with a rare and devastating lung disease: “When I think of IPF I think of... -Monday 29 February 2016    

International survey provides unique insights into the emotional truths of living with idiopathic pulmonary fibrosis (IPF) Worry and fear are the most common emotions experienced when diagnosed with IPF Patient support groups make people with IPF feel less isolated and provide access to...

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations -Thursday 25 February 2016

Pooled data from three key studies confirms that OFEV® slows disease progression by approximately 50% as measured by decline in forced vital capacity (FVC)*1-8 The pooled analysis also demonstrated that OFEV® significantly reduced the risk of acute exacerbations by...

Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site -Wednesday 23 December 2015  

• The total investment is around a half billion euro. • With this investment, Boehringer Ingelheim plans on adding more than 400 jobs. • The biopharmaceutical production plant will go into operation by 2021. (BUSINESS WIRE)-- Boehringer Ingelheim will make a significant investment...

Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site -Tuesday 22 December 2015

• The total investment is around a half billion euro. • With this investment, Boehringer Ingelheim plans on adding more than 400 jobs. • The biopharmaceutical production plant will go into operation by 2021. (BUSINESS WIRE)-- Boehringer Ingelheim will make a significant investment...

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer -Monday 21 December 2015

         New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer In 62% of patients with T790M-positive NSCLC objective responses were achieved, including...

Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to... -Friday 18 December 2015

12 abstracts for four compounds accepted including: new results from head-to-head trials comparing 2nd-generation EGFR TKI, afatinib, with 1st-generation EGFR TKIs, gefitinib and erlotinib Updated data for 3rd-generation EGFR TKI, BI 1482694, showing strong anti-tumour activity and...

Results 61-71 of 71